EcoDrugPlus

Amyloid Beta Precursor Protein

Ensembl ID : ENSMZEG00005005527
Gene Symbol: APP
4 Cross references
203 Possible Orthologues:

Amyloid-Beta A4 Protein

Ensembl ID : ENSMZEG00005022328
Gene Symbol: LOC101478308
3 Cross references
205 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSMZEG00005007428
Gene Symbol: AR
3 Cross references
212 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSMZEG00005007333
Gene Symbol: LOC101466282
2 Cross references
206 Possible Orthologues:

Anti-Apoptotic Protein Nr13

Ensembl ID : ENSMZEG00005008114
Gene Symbol: LOC101480331
3 Cross references
128 Possible Orthologues:

Apelin Receptor A-Like

Ensembl ID : ENSMZEG00005009189
Gene Symbol: LOC101478342
3 Cross references
171 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSMZEG00005015081
Gene Symbol: APH1A
3 Cross references
190 Possible Orthologues:

Apoptosis Regulator Bcl-2

Ensembl ID : ENSMZEG00005020046
Gene Symbol: LOC101477921
2 Cross references
168 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSMZEG00005014187
Gene Symbol: APEX1
3 Cross references
212 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s-Type

Ensembl ID : ENSMZEG00005022301
Gene Symbol: LOC101479810
3 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSMZEG00005027695
Gene Symbol: ALOX5
3 Cross references
225 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSMZEG00005024594
Gene Symbol: ALOX5AP
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).